AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days
AbbVie reported positive Phase 3 LUNA study results for atogepant, proving its efficacy and safety in preventing menstrual migraines.
AbbVie's new migraine medicine worked well in testing, which means the company may soon sell a drug that helps people with a specific type of headache. When a medicine passes big tests, it hints the company could have a useful product and more sales coming.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.